BACKGROUND: Exposure of critically ill patients to antibiotics lead to intestinal dysbiosis, which often manifests as antibiotic-associated diarrhoea. Faecal microbiota transplantation restores gut microbiota and may lead to faster resolution of diarrhoea. METHODS: Into this prospective, multi-centre, randomized controlled trial we will enrol 36 critically ill patients with antibiotic-associated diarrhoea. We will exclude patients with ongoing sepsis, need of systemic antibiotics, or those after recent bowel surgery or any other reason that prevents the FMT. Randomisation will be in 1:1 ratio. Patients in the control group will receive standard treatment based on oral diosmectite. In the intervention group, patients will receive, in addition to the standard of care, faecal microbiota transplantation via rectal tube, in the form of a preparation mixed from 7 thawed aliquots (50 mL) made from fresh stool of 7 healthy unrelated donors and quarantined deep frozen for 3 to 12 months. Primary outcome is treatment failure defined as intervention not delivered or diarrhoea persisting at day 7 after randomisation. Secondary outcomes include safety measures such as systemic inflammatory response, adverse events, and also diarrhoea recurrence within 28 days. Exploratory outcomes focus on gut barrier function and composition of intestinal microbiota. DISCUSSION: Faecal microbiota transplantation has been effective for dysbiosis in non-critically ill patients with recurrent C. difficile infections and it is plausible to hypothesize that it will be equally effective for symptoms of dysbiosis in the critically ill patients. In addition, animal experiments and observational data suggest other benefits such as reduced colonization with multi-drug resistant bacteria and improved gut barrier and immune function. The frozen faeces from unrelated donors are immediately available when needed, unlike those from the relatives, who require lengthy investigation. Using multiple donors maximises graft microbiota diversity. Nonetheless, in vulnerable critically ill patients, Faecal microbiota transplantation might lead to bacterial translocation and unforeseen complications. From growing number of case series it is clear that its off label use in the critically ill patients is increasing and that there is a burning need to objectively assess its efficacy and safety, which this trial aims. TRIAL REGISTRATION: www.clinicaltrials.gov (NCT05430269).

1st Department of Internal Medicine Faculty of Medicine in Pilsen Pilsen University Hospital Pilsen Czech Republic

3rd Department of Internal Medicine Metabolism and Gerontology Charles University Teaching Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Anaesthesia and Intensive Care Medicine Kralovske Vinohrady University Hospital Prague Czech Republic

Department of Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Microbiology Kralovske Vinohrady University Hospital Prague Czech Republic

Division of Gastroenterology Department of Internal Medicine Kralovske Vinohrady University Hospital Prague Czech Republic

The 3rd Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Rastelli M, Knauf C, Cani PD (2018) Gut Microbes and Health: A Focus on the Mechanisms Linking Microbes, Obesity, and Related Disorders. Obesity 26: 792–800. doi: 10.1002/oby.22175 PubMed DOI PMC

Keller JJ, Ooijevaar RE, Hvas CL, et al.. (2021) A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. United European Gastroenterol J 9: 229–247. doi: 10.1177/2050640620967898 PubMed DOI PMC

Lynch S V., Pedersen O (2016) The Human Intestinal Microbiome in Health and Disease. New England Journal of Medicine 375: 2369–2379. doi: 10.1056/NEJMra1600266 PubMed DOI

Ghosh TS, Rampelli S, Jeffery IB, et al.. (2020) Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: The NU-AGE 1-year dietary intervention across five European countries. Gut 69: 1218–1228. doi: 10.1136/gutjnl-2019-319654 PubMed DOI PMC

Vincent J-L, Rello J, Marshall J, et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. PubMed

McClave SA, Patel J, Bhutiani N (2018) Should fecal microbial transplantation be used in the ICU? Curr Opin Crit Care 24: 105–111. doi: 10.1097/MCC.0000000000000489 PubMed DOI

Hempel S, Newberry SJ, Maher AR, et al.. (2012) Probiotics for the Prevention and Treatment of Antibiotic-Associated Diarrhea A Systematic Review and Meta-analysis. PubMed

Cibulková I, Řehořová V, Hajer J, et al.. (2021) Fecal microbial transplantation in critically ill patients—Structured review and perspectives. Biomolecules 11. doi: 10.3390/biom11101459 PubMed DOI PMC

Wischmeyer PE, McDonald D, Knight R (2016) Role of the microbiome, probiotics, and ‘dysbiosis therapy’ in critical illness. Curr Opin Crit Care 22: 347–353. doi: 10.1097/MCC.0000000000000321 PubMed DOI PMC

Nakov R, Segal JP, Settanni CRS, et al.. (2020) Microbiome: What intensivists should know. Minerva Anestesiol 86: 777–785. doi: 10.23736/S0375-9393.20.14278-0 PubMed DOI

Liu W, Cheng M, Li J, et al.. (2020) Classification of the Gut Microbiota of Patients in Intensive Care Units During Development of Sepsis and Septic Shock. Genomics Proteomics Bioinformatics 18: 696–707. doi: 10.1016/j.gpb.2020.06.011 PubMed DOI PMC

Bloos F, Thomas-Rüddel D, Rüddel H, et al.. (2014) Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: A prospective observational multi-center study. Crit Care 18. doi: 10.1186/cc13755 PubMed DOI PMC

Arulkumaran N, Routledge M, Schlebusch S, et al.. (2020) Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Med 46: 225–235. doi: 10.1007/s00134-020-05929-3 PubMed DOI PMC

Gibson Y, Roberfroid MB (1995) Dietary Modulation of the Human Colonie Microbiota: Introducing the Concept of Prebiotics. PubMed

Kim SK, Guevarra RB, Kim YT, et al.. (2019) Role of probiotics in human gut microbiome-associated diseases. J Microbiol Biotechnol 29: 1335–1340. doi: 10.4014/jmb.1906.06064 PubMed DOI

Su GL, Ko CW, Bercik P, et al.. (2020) AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology 159: 697–705. doi: 10.1053/j.gastro.2020.05.059 PubMed DOI

Batra P, Soni KD, Mathur P (2020) Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials. J Intensive Care 8. doi: 10.1186/s40560-020-00487-8 PubMed DOI PMC

Shimizu K, Hirose T, Ogura H (2021) Efficacy of probiotics in the prevention of diarrhea in ventilated critically ill ICU patients: meta-analysis of randomized control trials. J Intensive Care 9. doi: 10.1186/s40560-021-00567-3 PubMed DOI PMC

Manzanares W, Lemieux M, Langlois PL, et al.. (2016) Probiotic and synbiotic therapy in critical illness: A systematic review and meta-analysis. Crit Care 20. doi: 10.1186/s13054-016-1434-y PubMed DOI PMC

Muñ oz P, Bouza E, Cuenca-Estrella M, et al.. (2005) Saccharomyces cerevisiae Fungemia: An Emerging Infectious Disease. Clinical Infectious Diseases 1625–1634. doi: 10.1086/429916 PubMed DOI

Bongaerts GPA, Severijnen RSVM (2016) A reassessment of the PROPATRIA study and its implications for probiotic therapy. Nat Biotechnol 34: 55–63. doi: 10.1038/nbt.3436 PubMed DOI

Brandt LJ (2012) Response to Zhang et al.. American Journal of Gastroenterology 107: 1755–1756. PubMed

Borody TJ, Warren EF, Leis SM, et al.. (2004) Bacteriotherapy Using Fecal Flora Toying With Human Motions. PubMed

Jarmo O, Veli-Jukka A, Eero M (2020) Treatment of Clostridioides (Clostridium) difficile infection. Ann Med 52: 12–20. doi: 10.1080/07853890.2019.1701703 PubMed DOI PMC

Kelly CR, Fischer M, Allegretti JR, et al.. (2021) ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 116: 1124–1147. doi: 10.14309/ajg.0000000000001278 PubMed DOI

Alukal J, Dutta SK, Surapaneni BK, et al.. (2019) Safety and efficacy of fecal microbiota transplant in 9 critically ill patients with severe and complicated Clostridium difficile infection with impending colectomy. J Dig Dis 20: 301–307. doi: 10.1111/1751-2980.12750 PubMed DOI

Ianiro G, Masucci L, Quaranta G, et al.. (2018) Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions. Aliment Pharmacol Ther 48: 152–159. doi: 10.1111/apt.14816 PubMed DOI

Cheng Y-WMHXEPNRSSMBZKMJAMMFM (2017) Fecal Microbiota Transplant Decreases Mortality in Patients With Refractory Severe and Severe Complicated Clostridium difficile Infection Not Eligible for Colectomy. American Journal of Gastroenterology 112: 100.

Ubeda C, Bucci V, Caballero S, et al.. (2013) Intestinal microbiota containing Barnesiella species cures vancomycin-resistant Enterococcus faecium colonization. Infect Immun 81: 965–973. doi: 10.1128/IAI.01197-12 PubMed DOI PMC

Bilinski J, Grzesiowski P, Sorensen N, et al.. (2017) Fecal Microbiota Transplantation in Patients With Blood Disorders Inhibits Gut Colonization With Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study. Clinical Infectious Diseases 65: 364–370. doi: 10.1093/cid/cix252 PubMed DOI

Karakan T, İbiş M, Cindoruk M, et al.. P639 Faecal microbiota transplantation as a rescue therapy for steroid-dependent and/or non-responsive patients with ulcerative colitis: a pilot study. P640 Co-detection of infliximab and antibodies in an ECLIA assay amongst IBD patients treated with infliximab.

Fischer M, Kao D, Kelly C, et al.. (2016) Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 22: 2402–2409. doi: 10.1097/MIB.0000000000000908 PubMed DOI

Costello SP, Day A, Yao CK, et al.. (2020) Faecal microbiota transplantation (FMT) with dietary therapy for acute severe ulcerative colitis. BMJ Case Rep 13. doi: 10.1136/bcr-2019-233135 PubMed DOI PMC

Li Q, Wang C, Tang C, et al.. (2015) Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: A case report. Crit Care 19. doi: 10.1186/s13054-015-0738-7 PubMed DOI PMC

Wei Y, Yang J, Wang J, et al.. (2016) Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. Crit Care 20. doi: 10.1186/s13054-016-1491-2 PubMed DOI PMC

Dai M, Liu Y, Chen W, et al.. (2019) Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients. Crit Care 23. doi: 10.1186/s13054-019-2604-5 PubMed DOI PMC

An-Wen Chan 1 JMTPCGDGAHMJABKDAHKFSWRPKK-JALDM (2013) SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. doi: 10.1136/bmj.e7586 PubMed DOI PMC

Jorup-Rönström C, Håkanson A, Sandell S, et al.. (2012) Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 47: 548–552. doi: 10.3109/00365521.2012.672587 PubMed DOI

Juul FE, Garborg K, Bretthauer M, et al.. (2018) Fecal Microbiota Transplantation for Primary Clostridium difficile Infection. New England Journal of Medicine 378: 2535–2536. doi: 10.1056/NEJMc1803103 PubMed DOI

Zhou H, Xu Q, Liu Y, et al.. (2020) Risk factors, incidence, and morbidity associated with antibioticassociated diarrhea in intensive care unit patients receiving antibiotic monotherapy. World J Clin Cases 8: 1908–1915. doi: 10.12998/wjcc.v8.i10.1908 PubMed DOI PMC

Chumpitazi BP, Self MM, Czyzewski DI, et al.. (2016) Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterology and Motility 28: 443–448. doi: 10.1111/nmo.12738 PubMed DOI PMC

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15. doi: 10.1186/s13059-014-0550-8 PubMed DOI PMC

Alagna L, Haak BW, Gori A (2019) Fecal microbiota transplantation in the ICU: perspectives on future implementations. Intensive Care Med 45: 998–1001. doi: 10.1007/s00134-019-05645-7 PubMed DOI

Wei Y, Gong J, Zhu W, et al.. (2015) Fecal microbiota transplantation restores dysbiosis in patients with methicillin resistant Staphylococcus aureus enterocolitis. BMC Infect Dis 15. doi: 10.1186/s12879-015-0973-1 PubMed DOI PMC

Gopalsamy SN, Sherman A, Woodworth MH, et al.. (2018) Fecal Microbiota Transplant for Multidrug-Resistant Organism Decolonization Administered during Septic Shock. Infect Control Hosp Epidemiol 39: 490–492. doi: 10.1017/ice.2017.300 PubMed DOI PMC

Ueckermann V, Hoosien E, De Villiers N, et al.. (2020) Fecal Microbial Transplantation for the Treatment of Persistent Multidrug-Resistant K lebsiella pneumoniae Infection in a Critically Ill Patient. Case Rep Infect Dis 2020: 1–5. PubMed PMC

Huttner BD, de Lastours V, Wassenberg M, et al.. (2019) A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clinical Microbiology and Infection 25: 830–838. doi: 10.1016/j.cmi.2018.12.009 PubMed DOI

Schuijt TJ, van der Poll T, de Vos WM, et al.. (2013) The intestinal microbiota and host immune interactions in the critically ill. Trends Microbiol 21: 221–229. doi: 10.1016/j.tim.2013.02.001 PubMed DOI

Fischer M, Sipe BW, Rogers NA, et al.. (2015) Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 42: 470–476. doi: 10.1111/apt.13290 PubMed DOI

Zainah H, Hassan M, Shiekh-Sroujieh L, et al.. (2015) Intestinal Microbiota Transplantation, a Simple and Effective Treatment for Severe and Refractory Clostridium Difficile Infection. Dig Dis Sci 60: 181–185. doi: 10.1007/s10620-014-3296-y PubMed DOI

Luo Y, Tixier EN, Grinspan AM (2020) Fecal Microbiota Transplantation for Clostridioides difficile in High-Risk Older Adults Is Associated with Early Recurrence. Dig Dis Sci 65: 3647–3651. doi: 10.1007/s10620-020-06147-z PubMed DOI

Aroniadis OC, Brandt LJ, Greenberg A, et al.. (2015) Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection A Multicenter Experience. PubMed

Agrawal M, Aroniadis OC, Brandt LJ, et al.. (2015) The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. PubMed

Cammarota Giovanni (2015) Decrease in Surgery for Clostridium difficile Infection After Starting a Program to Transplant Fecal Microbiota. Ann Intern Med 162: 533–541. PubMed

You DM, Franzos MA, Holman RP (2008) Successful Treatment of Fulminant Clostridium difficile Infection with Fecal Bacteriotherapy. Ann Intern Med 148. PubMed

Yu S, Abdelkarim A, Nawras A, et al. Fecal Transplant for Treatment of Toxic Megacolon Associated With Clostridium Difficile Colitis in a Patient With Duchenne Muscular Dystrophy. PubMed

Řehořová V, Cibulková I, Soukupová H, et al.. (2021) Multi-donor Fecal Microbial Transplantation for Critically Ill Patients: Rationale and Standard Operating Procedure.

Paramsothy S, Kamm MA, Kaakoush NO, et al.. (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. The Lancet 389: 1218–1228. doi: 10.1016/S0140-6736(17)30182-4 PubMed DOI

Taur Y, Coyte K, Schluter J, et al.. (2018) Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med 10. doi: 10.1126/scitranslmed.aap9489 PubMed DOI PMC

Cammarota G, Ianiro G, Kelly CR, et al.. (2019) International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 68: 2111–2121. doi: 10.1136/gutjnl-2019-319548 PubMed DOI PMC

van Prehn J, Reigadas E, Vogelzang EH, et al.. (2021) European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical Microbiology and Infection.</References> doi: 10.1016/j.cmi.2021.09.038 PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT05430269